Presentations & Publications
IpY.20: Innovative strategies for post-CDK estrogen receptor (ER)+ metastatic breast cancer (mBC)
Drugging p27 to inhibit CDK2/4/6 together
Triple CDK2/4/6 inhibition via p27 modulation: A novel approach to targeting cell cycle dysregulation
IpY.20, a first-in-class inhibitor of p27Kip1, inhibits CDK4/6 and CDK2 to kill tumor cell
Concarlo in the News
AFCR Announces Winner of the 2024 BRACE Award Venture Competition
Concarlo Therapeutics Presents Novel Therapeutic Approach for ER+ Metastatic Breast Cancer Targeting the CDK Pathway
Many startups are built off research, so why don’t more scientists become founders?
Paving the Way: Bold Perspectives from Female Executives in Biotech featuring Krishna Allamneni
Webinars & Talks
Concarlo Therapeutics at Evercore ISI 2024 Emerging Biotech Conference
Beyond Biotech podcast 24: Concarlo Therapeutics
The academic to founder pipeline with Dr. Stacy Blain from Concarlo Therapeutics
Stacy Blain and Arthur Klausner on NewYorkBIOs Virtual Breakfast Series
Awards
“The reward for work well done is the opportunity to do more”
—Jonas Salk
The 50 Most admired companies: CIO Bio
Top 100 entreprenuers: Alumni List
Top Biotech Startup 2022
Awarded by: Life Sciences Review
